Targeted therapy of multiple myeloma: The changing paradigm at the beginning of the new millennium

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 743-756

  Morabito, Fortunato ^a   Recchia, Anna Grazia ^a   Mazzone, Carla ^a   Gentile, Massimo ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

Author keywords

Bortezomib; Lenalidomide; Multiple myeloma; Stem cell transplantation; Thalidomide; Therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; DICKKOPF 1 PROTEIN; DIURETIC AGENT; ERYTHROPOIETIN; LENALIDOMIDE; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PREDNISONE; STEROID; THALIDOMIDE; WNT PROTEIN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER RADIOTHERAPY; DRUG EFFICACY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HYDRATION; HYPERCALCEMIA; HYPERURICEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84866423778     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429373     Document Type: Article

References (117)

1. Kyle, R. A.; Rajkumar, S. V. Multiple myeloma. N. Engl. J. Med. 2004, 351 (18), 1860-1873 [Erratum, N. Engl. J. Med. 2005, 352, 1163].
2. Kyle, R. A.; Gertz, M. A.; Witzig, T. E.; Lust, J. A.; Lacy, M. Q.; Dispenzieri, A.; Fonseca, R.; Rajkumar, S. V.; Offord, J. R.; Larson, D. R.; Plevak, M. E.; Therneau, T. M.; Greipp, P. R. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo. Clin. Proc. 2003, 78 (1), 21-33.
3. Landgren, O.; Kyle, R. A.; Pfeiffer, R. M.; Katzmann, J. A.; Caporaso, N. E.; Hayes, R. B.; Dispenzieri, A.; Kumar, S.; Clark, R. J.; Baris, D.; Hoover, R.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113 (22), 5412-5417.
4. Weiss, B. M.; Abadie, J.; Verma, P.; Howard, R. S.; Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113 (22), 5418-5422.
5. Blade, J.; Rosinol, L.; Cibeira, M. T. Are all myelomas preceded by MGUS? Blood 2009, 113 (22), 5370.
6. Ferlay, J.; Bray, F.; Sankila, R.; Parkin, D. M. EUCAN: Cancer Incidence, Mortality and Prevalence in the European Union 1998, version 5.0. IARC Cancer Base No 4. IARC Press: Lyon, France, 1999.
7. Parker, S. L.; Davis, K. J.; Wingo, P. A.; Ries, L. A.; Heath, C. W. Jr. Cancer statistics by race and ethnicity. CA. Cancer J. Clin. 1998, 48 (1), 31-48.
8. Raab, M. S.; Podar, K.; Breitkreutz, I.; Richardson, P. G.; Anderson, K. C. Multiple myeloma. Lancet 2009, 374 (9686), 324-339.
9. Ludwig, H.; Bolejack, V.; Crowley, J.; Blade, J.; Miguel, J. S.; Kyle, R. A.; Rajkumar, S. V.; Shimizu, K.; Turesson, I.; Westin, J.; Sonneveld, P.; Cavo, M.; Boccadoro, M.; Palumbo, A.; Tosi, P.; Harousseau, J. L.; Attal, M.; Barlogie, B.; Stewart, A. K.; Durie, B. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J. Clin. Oncol. 2010, 28 (9), 1599-1605.
10. Kristinsson, S. Y.; Landgren, O.; Dickman, P. W.; Derolf, A. R.; Bjorkholm, M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J. Clin. Oncol. 2007, 25 (15), 1993-1999.
11. Brenner, H.; Gondos, A.; Pulte, D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111 (5), 2521-2526.
12. Kumar, S. K.; Rajkumar, S. V.; Dispenzieri, A.; Lacy, M. Q.; Hayman, S. R.; Buadi, F. K.; Zeldenrust, S. R.; Dingli, D.; Russell, S. J.; Lust, J. A.; Greipp, P. R.; Kyle, R. A.; Gertz, M. A. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111 (5), 2516-2520.
13. Durie, B. G.; Kyle, R. A.; Belch, A.; Bensinger, W.; Blade, J.; Boccadoro, M.; Child, J. A.; Comenzo, R.; Djulbegovic, B.; Fantl, D.; Gahrton, G.; Harousseau, J. L.; Hungria, V.; Joshua, D.; Ludwig, H.; Mehta, J.; Morales, A. R.; Morgan, G.; Nouel, A.; Oken, M.; Powles, R.; Roodman, D.; San Miguel, J.; Shimizu, K.; Singhal, S.; Sirohi, B.; Sonneveld, P.; Tricot, G.; Van Ness, B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol. J. 2003, 4 (6), 379-398. [Erratum, Hematol. J. 2004, 5 (3), 285].
14. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 2003, 121 (5), 749-757.
15. Terpos, E.; Moulopoulos, L. A.; Dimopoulos, M. A. Advances in imaging and the management of myeloma bone disease. J. Clin. Oncol. 2011, 29 (14), 1907-1915.
16. Durie, B. G.; Salmon, S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36 (3), 842-854.
17. Greipp, P. R.; San Miguel, J.; Durie, B. G.; Crowley, J. J.; Barlogie, B.; Blade, J.; Boccadoro, M.; Child, J. A.; Avet-Loiseau, H.; Kyle, R. A.; Lahuerta, J. J.; Ludwig, H.; Morgan, G.; Powles, R.; Shimizu, K.; Shustik, C.; Sonneveld, P.; Tosi, P.; Turesson, I.; Westin, J. International staging system for multiple myeloma. J. Clin. Oncol. 2005, 23 (15), 3412-3420.
18. Snozek, C. L.; Katzmann, J. A.; Kyle, R. A.; Dispenzieri, A.; Larson, D. R.; Therneau, T. M.; Melton, L. J., 3rd; Kumar, S.; Greipp, P. R.; Clark, R. J.; Rajkumar, S. V. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008, 22 (10), 1933-1937.
19. Jakob, C.; Sterz, J.; Liebisch, P.; Mieth, M.; Rademacher, J.; Goerke, A.; Heider, U.; Fleissner, C.; Kaiser, M.; von Metzler, I.; Muller, C.; Sezer, O. Incorporation of the bone marker carboxyterminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008, 22 (9), 1767-1772.
20. Durie, B. G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur. J. Cancer 2006, 42 (11), 1539-1543.
21. Zamagni, E.; Patriarca, F.; Nanni, C.; Zannetti, B.; Englaro, E.; Pezzi, A.; Tacchetti, P.; Buttignol, S.; Perrone, G.; Brioli, A.; Pantani, L.; Terragna, C.; Carobolante, F.; Baccarani, M.; Fanin, R.; Fanti, S.; Cavo, M. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with upfront autologous transplantation. Blood 2011, 118 (23), 5989-5995.
22. Gertz, M. A.; Lacy, M. Q.; Dispenzieri, A.; Greipp, P. R.; Litzow, M. R.; Henderson, K. J.; Van Wier, S. A.; Ahmann, G. J.; Fonseca, R. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106 (8), 2837-2840.
23. Zhan, F.; Huang, Y.; Colla, S.; Stewart, J. P.; Hanamura, I.; Gupta, S.; Epstein, J.; Yaccoby, S.; Sawyer, J.; Burington, B.; Anaissie, E.; Hollmig, K.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B.; Shaughnessy, J. D. Jr. The molecular classification of multiple myeloma. Blood 2006, 108 (6), 2020-2028.
24. Avet-Loiseau, H.; Attal, M.; Moreau, P.; Charbonnel, C.; Garban, F.; Hulin, C.; Leyvraz, S.; Michallet, M.; Yakoub-Agha, I.; Garderet, L.; Marit, G.; Michaux, L.; Voillat, L.; Renaud, M.; Grosbois, B.; Guillerm, G.; Benboubker, L.; Monconduit, M.; Thieblemont, C.; Casassus, P.; Caillot, D.; Stoppa, A. M.; Sotto, J. J.; Wetterwald, M.; Dumontet, C.; Fuzibet, J. G.; Azais, I.; Dorvaux, V.; Zandecki, M.; Bataille, R.; Minvielle, S.; Harousseau, J. L.; Facon, T.; Mathiot, C. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109 (8), 3489-3495.
25. Stewart, A. K.; Bergsagel, P. L.; Greipp, P. R.; Dispenzieri, A.; Gertz, M. A.; Hayman, S. R.; Kumar, S.; Lacy, M. Q.; Lust, J. A.; Russell, S. J.; Witzig, T. E.; Zeldenrust, S. R.; Dingli, D.; Reeder, C. B.; Roy, V.; Kyle, R. A.; Rajkumar, S. V.; Fonseca, R. A practical guide to defining high-risk myeloma for clinical trials, atient counseling and choice of therapy. Leukemia 2007, 21 (3), 529-534.
26. San Miguel, J. F.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Mateos, M. V.; Anderson, K. C.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P. G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359 (9), 906-917.
27. Avet-Loiseau, H.; Leleu, X.; Roussel, M.; Moreau, P.; Guerin-Charbonnel, C.; Caillot, D.; Marit, G.; Benboubker, L.; Voillat, L.; Mathiot, C.; Kolb, B.; Macro, M.; Campion, L.; Wetterwald, M.; Stoppa, A. M.; Hulin, C.; Facon, T.; Attal, M.; Minvielle, S.; Harousseau, J. L. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J. Clin. Oncol. 2010, 28 (30), 4630-4634.
28. Kapoor, P.; Kumar, S.; Fonseca, R.; Lacy, M. Q.; Witzig, T. E.; Hayman, S. R.; Dispenzieri, A.; Buadi, F.; Bergsagel, P. L.; Gertz, M. A.; Dalton, R. J.; Mikhael, J. R.; Dingli, D.; Reeder, C. B.; Lust, J. A.; Russell, S. J.; Roy, V.; Zeldenrust, S. R.; Stewart, A. K.; Kyle, R. A.; Greipp, P. R.; Rajkumar, S. V. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009, 114 (3), 518-521.
29. Kapoor, P.; Fonseca, R.; Rajkumar, S. V.; Sinha, S.; Gertz, M. A.; Stewart, A. K.; Bergsagel, P. L.; Lacy, M. Q.; Dingli, D. D.; Ketterling, R. P.; Buadi, F.; Kyle, R. A.; Witzig, T. E.; Greipp, P. R.; Dispenzieri, A.; Kumar, S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo. Clin. Proc. 2010, 85 (6), 532-537.
30. Fonseca, R.; Bergsagel, P. L.; Drach, J.; Shaughnessy, J.; Gutierrez, N.; Stewart, A. K.; Morgan, G.; Van Ness, B.; Chesi, M.; Minvielle, S.; Neri, A.; Barlogie, B.; Kuehl, W. M.; Liebisch, P.; Davies, F.; Chen-Kiang, S.; Durie, B. G.; Carrasco, R.; Sezer, O.; Reiman, T.; Pilarski, L.; Avet-Loiseau, H. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009, 23 (12), 2210-2221.
31. Shaughnessy, J. D. Jr.; Zhan, F.; Burington, B. E.; Huang, Y.; Colla, S.; Hanamura, I.; Stewart, J. P.; Kordsmeier, B.; Randolph, C.; Williams, D. R.; Xiao, Y.; Xu, H.; Epstein, J.; Anaissie, E.; Krishna, S. G.; Cottler-Fox, M.; Hollmig, K.; Mohiuddin, A.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Sawyer, J.; Alsayed, Y.; Walker, R.; Zangari, M.; Crowley, J.; Barlogie, B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109 (6), 2276-2284.
32. Decaux, O.; Lode, L.; Magrangeas, F.; Charbonnel, C.; Gouraud, W.; Jezequel, P.; Attal, M.; Harousseau, J. L.; Moreau, P.; Bataille, R.; Campion, L.; Avet-Loiseau, H.; Minvielle, S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J. Clin. Oncol. 2008, 26 (29), 4798-4805.
33. Carrasco, D. R.; Tonon, G.; Huang, Y.; Zhang, Y.; Sinha, R.; Feng, B.; Stewart, J. P.; Zhan, F.; Khatry, D.; Protopopova, M.; Protopopov, A.; Sukhdeo, K.; Hanamura, I.; Stephens, O.; Barlogie, B.; Anderson, K. C.; Chin, L.; Shaughnessy, J. D. Jr.; Brennan, C.; Depinho, R. A. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006, 9 (4), 313-325.
34. Agnelli, L.; Forcato, M.; Ferrari, F.; Tuana, G.; Todoerti, K.; Walker, B. A.; Morgan, G. J.; Lombardi, L.; Bicciato, S.; Neri, A. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin. Cancer Res. 2011, 17 (23), 7402-7412.
35. Davies, F. E.; Dring, A. M.; Li, C.; Rawstron, A. C.; Shammas, M. A.; O'Connor, S. M.; Fenton, J. A.; Hideshima, T.; Chauhan, D.; Tai, I. T.; Robinson, E.; Auclair, D.; Rees, K.; Gonzalez, D.; Ashcroft, A. J.; Dasgupta, R.; Mitsiades, C.; Mitsiades, N.; Chen, L. B.; Wong, W. H.; Munshi, N. C.; Morgan, G. J.; Anderson, K. C. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003, 102 (13), 4504-4511.
36. Broyl, A.; Hose, D.; Lokhorst, H.; de Knegt, Y.; Peeters, J.; Jauch, A.; Bertsch, U.; Buijs, A.; Stevens-Kroef, M.; Beverloo, H. B.; Vellenga, E.; Zweegman, S.; Kersten, M. J.; van der Holt, B.; el Jarari, L.; Mulligan, G.; Goldschmidt, H.; van Duin, M.; Sonneveld, P. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010, 116 (14), 2543-2553.
37. Munshi, N. C.; Avet-Loiseau, H. Genomics in multiple myeloma. Clin. Cancer Res. 2011, 17 (6), 1234-1242.
38. Avet-Loiseau, H.; Li, C.; Magrangeas, F.; Gouraud, W.; Charbonnel, C.; Harousseau, J. L.; Attal, M.; Marit, G.; Mathiot, C.; Facon, T.; Moreau, P.; Anderson, K. C.; Campion, L.; Munshi, N. C.; Minvielle, S. Prognostic significance of copy-number alterations in multiple myeloma. J. Clin. Oncol. 2009, 27 (27), 4585-4590.
39. van de Velde, H. J.; Liu, X.; Chen, G.; Cakana, A.; Deraedt, W.; Bayssas, M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007, 92 (10), 1399-1406.
40. Palumbo, A.; Anderson, K. Multiple myeloma. N. Engl. J. Med. 2011, 364 (11), 1046-1060.
41. Kyle, R. A.; Rajkumar, S. V. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 2009, 9 (4), 278-288.
42. Blade, J.; Dimopoulos, M.; Rosinol, L.; Rajkumar, S. V.; Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 2010, 28 (4), 690-697.
43. Kyle, R. A.; Remstein, E. D.; Therneau, T. M.; Dispenzieri, A.; Kurtin, P. J.; Hodnefield, J. M.; Larson, D. R.; Plevak, M. F.; Jelinek, D. F.; Fonseca, R.; Melton, L. J. 3rd; Rajkumar, S. V. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007, 356 (25), 2582-2590.
44. Kyle, R. A.; Durie, B. G.; Rajkumar, S. V.; Landgren, O.; Blade, J.; Merlini, G.; Kroger, N.; Einsele, H.; Vesole, D. H.; Dimopoulos, M.; San Miguel, J.; Avet-Loiseau, H.; Hajek, R.; Chen, W. M.; Anderson, K. C.; Ludwig, H.; Sonneveld, P.; Pavlovsky, S.; Palumbo, A.; Richardson, P. G.; Barlogie, B.; Greipp, P.; Vescio, R.; Turesson, I.; Westin, J.; Boccadoro, M. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24 (6), 1121-1127.
45. Stewart, A. K.; Richardson, P. G.; San-Miguel, J. F. How I treat multiple myeloma in younger patients. Blood 2009, 114 (27), 5436-5443.
46. Palumbo, A.; Bringhen, S.; Rossi, D.; Cavalli, M.; Larocca, A.; Ria, R.; Offidani, M.; Patriarca, F.; Nozzoli, C.; Guglielmelli, T.; Benevolo, G.; Callea, V.; Baldini, L.; Morabito, F.; Grasso, M.; Leonardi, G.; Rizzo, M.; Falcone, A. P.; Gottardi, D.; Montefusco, V.; Musto, P.; Petrucci, M. T.; Ciccone, G.; Boccadoro, M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 2010, 28 (34), 5101-5109.
47. Palumbo, A.; Sezer, O.; Kyle, R.; Miguel, J. S.; Orlowski, R. Z.; Moreau, P.; Niesvizky, R.; Morgan, G.; Comenzo, R.; Sonneveld, P.; Kumar, S.; Hajek, R.; Giralt, S.; Bringhen, S.; Anderson, K. C.; Richardson, P. G.; Cavo, M.; Davies, F.; Blade, J.; Einsele, H.; Dimopoulos, M. A.; Spencer, A.; Dispenzieri, A.; Reiman, T.; Shimizu, K.; Lee, J. H.; Attal, M.; Boccadoro, M.; Mateos, M.; Chen, W.; Ludwig, H.; Joshua, D.; Chim, J.; Hungria, V.; Turesson, I.; Durie, B. G.; Lonial, S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23 (10), 1716-1730.
48. Garban, F.; Attal, M.; Michallet, M.; Hulin, C.; Bourhis, J. H.; Yakoub-Agha, I.; Lamy, T.; Marit, G.; Maloisel, F.; Berthou, C.; Dib, M.; Caillot, D.; Deprijck, B.; Ketterer, N.; Harousseau, J. L.; Sotto, J. J.; Moreau, P. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107 (9), 3474-3480.
49. Rosinol, L.; Perez-Simon, J. A.; Sureda, A.; de la Rubia, J.; de Arriba, F.; Lahuerta, J. J.; Gonzalez, J. D.; Diaz-Mediavilla, J.; Hernandez, B.; Garcia-Frade, J.; Carrera, D.; Leon, A.; Hernandez, M.; Abellan, P. F.; Bergua, J. M.; San Miguel, J.; Blade, J. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112 (9), 3591-3593.
50. Bruno, B.; Rotta, M.; Patriarca, F.; Mattei, D.; Allione, B.; Carnevale-Schianca, F.; Sorasio, R.; Rambaldi, A.; Casini, M.; Parma, M.; Bavaro, P.; Onida, F.; Busca, A.; Castagna, L.; Benedetti, E.; Iori, A. P.; Giaccone, L.; Palumbo, A.; Corradini, P.; Fanin, R.; Maloney, D.; Storb, R.; Baldi, I.; Ricardi, U.; Boccadoro, M. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009, 113 (14), 3375-3382.
51. Bruno, B.; Rotta, M.; Patriarca, F.; Mordini, N.; Allione, B.; Carnevale-Schianca, F.; Giaccone, L.; Sorasio, R.; Omede, P.; Baldi, I.; Bringhen, S.; Massaia, M.; Aglietta, M.; Levis, A.; Gallamini, A.; Fanin, R.; Palumbo, A.; Storb, R.; Ciccone, G.; Boccadoro, M. A comparison of allografting with autografting for newly diagnosed myeloma. N. Engl. J. Med. 2007, 356 (11), 1110-1120.
52. Durie, B. G.; Harousseau, J. L.; Miguel, J. S.; Blade, J.; Barlogie, B.; Anderson, K.; Gertz, M.; Dimopoulos, M.; Westin, J.; Sonneveld, P.; Ludwig, H.; Gahrton, G.; Beksac, M.; Crowley, J.; Belch, A.; Boccadaro, M.; Cavo, M.; Turesson, I.; Joshua, D.; Vesole, D.; Kyle, R.; Alexanian, R.; Tricot, G.; Attal, M.; Merlini, G.; Powles, R.; Richardson, P.; Shimizu, K.; Tosi, P.; Morgan, G.; Rajkumar, S. V. International uniform response criteria for multiple myeloma. Leukemia 2006, 20 (9), 1467-1473. [Erratum, Leukemia 2006, 20 (12), 2220; 2007, 21 (5), 1134].
53. Kyle, R. A.; Rajkumar, S. V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23 (1), 3-9.
54. Dispenzieri, A.; Kyle, R.; Merlini, G.; Miguel, J. S.; Ludwig, H.; Hajek, R.; Palumbo, A.; Jagannath, S.; Blade, J.; Lonial, S.; Dimopoulos, M.; Comenzo, R.; Einsele, H.; Barlogie, B.; Anderson, K.; Gertz, M.; Harousseau, J. L.; Attal, M.; Tosi, P.; Sonneveld, P.; Boccadoro, M.; Morgan, G.; Richardson, P.; Sezer, O.; Mateos, M. V.; Cavo, M.; Joshua, D.; Turesson, I.; Chen, W.; Shimizu, K.; Powles, R.; Rajkumar, S. V.; Durie, B. G. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23 (2), 215-224.
55. Lahuerta, J. J.; Mateos, M. V.; Martinez-Lopez, J.; Rosinol, L.; Sureda, A.; de la Rubia, J.; Garcia-Larana, J.; Martinez-Martinez, R.; Hernandez-Garcia, M. T.; Carrera, D.; Besalduch, J.; de Arriba, F.; Ribera, J. M.; Escoda, L.; Hernandez-Ruiz, B.; Garcia-Frade, J.; Rivas-Gonzalez, C.; Alegre, A.; Blade, J.; San Miguel, J. F. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 2008, 26 (35), 5775-5782.
56. Palumbo, A.; Bringhen, S.; Liberati, A. M.; Caravita, T.; Falcone, A.; Callea, V.; Montanaro, M.; Ria, R.; Capaldi, A.; Zambello, R.; Benevolo, G.; Derudas, D.; Dore, F.; Cavallo, F.; Gay, F.; Falco, P.; Ciccone, G.; Musto, P.; Cavo, M.; Boccadoro, M. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008, 112 (8), 3107-3114.
57. Harousseau, J. L.; Palumbo, A.; Richardson, P. G.; Schlag, R.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Kentos, A.; Cavo, M.; Golenkov, A.; Komarnicki, M.; Mateos, M. V.; Esseltine, D. L.; Cakana, A.; Liu, K.; Deraedt, W.; van de Velde, H.; San Miguel, J. F. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalanprednisone. Blood 2010, 116 (19), 3743-3750.
58. Harousseau, J. L.; Dimopoulos, M. A.; Wang, M.; Corso, A.; Chen, C.; Attal, M.; Spencer, A.; Yu, Z.; Olesnyckyj, M.; Zeldis, J. B.; Knight, R. D.; Weber, D. M. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010, 95 (10), 1738-1744.
59. Paiva, B.; Vidriales, M. B.; Cervero, J.; Mateo, G.; Perez, J. J.; Montalban, M. A.; Sureda, A.; Montejano, L.; Gutierrez, N. C.; Garcia de Coca, A.; de Las Heras, N.; Mateos, M. V.; Lopez- Berges, M. C.; Garcia-Boyero, R.; Galende, J.; Hernandez, J.; Palomera, L.; Carrera, D.; Martinez, R.; de la Rubia, J.; Martin, A.; Blade, J.; Lahuerta, J. J.; Orfao, A.; San Miguel, J. F. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112 (10), 4017-4023.
60. Ladetto, M.; Pagliano, G.; Ferrero, S.; Cavallo, F.; Drandi, D.; Santo, L.; Crippa, C.; De Rosa, L.; Pregno, P.; Grasso, M.; Liberati, A. M.; Caravita, T.; Pisani, F.; Guglielmelli, T.; Callea, V.; Musto, P.; Cangialosi, C.; Passera, R.; Boccadoro, M.; Palumbo, A. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J. Clin. Oncol. 2010, 28 (12), 2077-2084.
61. Barlogie, B.; Anaissie, E.; Haessler, J.; van Rhee, F.; Pineda- Roman, M.; Hollmig, K.; Alsayed, Y.; Epstein, J.; Shaughnessy, J. D. Jr.; Crowley, J. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008, 113 (2), 355-359.
62. Attal, M.; Harousseau, J. L.; Leyvraz, S.; Doyen, C.; Hulin, C.; Benboubker, L.; Yakoub Agha, I.; Bourhis, J. H.; Garderet, L.; Pegourie, B.; Dumontet, C.; Renaud, M.; Voillat, L.; Berthou, C.; Marit, G.; Monconduit, M.; Caillot, D.; Grobois, B.; Avet-Loiseau, H.; Moreau, P.; Facon, T. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108 (10), 3289-3294.
63. Spencer, A.; Prince, H. M.; Roberts, A. W.; Prosser, I. W.; Bradstock, K. F.; Coyle, L.; Gill, D. S.; Horvath, N.; Reynolds, J.; Kennedy, N. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 2009, 27 (11), 1788-1793.
64. Barlogie, B.; Tricot, G.; Anaissie, E.; Shaughnessy, J.; Rasmussen, E.; van Rhee, F.; Fassas, A.; Zangari, M.; Hollmig, K.; Pineda-Roman, M.; Lee, C.; Talamo, G.; Thertulien, R.; Kiwan, E.; Krishna, S.; Fox, M.; Crowley, J., Thalidomide and hematopoieticcell transplantation for multiple myeloma. N. Engl. J. Med. 2006, 354 (10), 1021-1030.
65. Ludwig, H.; Adam, Z.; Tothova, E.; Hajek, R.; Labar, B.; Egyed, M.; Spicka, I.; Gisslinger, H.; Drach, J.; Kuhn, I.; Hinke, A.; Zojer, N., Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010, 95 (9), 1548-1554.
66. Kumar, S. K.; Mikhael, J. R.; Buadi, F. K.; Dingli, D.; Dispenzieri, A.; Fonseca, R.; Gertz, M. A.; Greipp, P. R.; Hayman, S. R.; Kyle, R. A.; Lacy, M. Q.; Lust, J. A.; Reeder, C. B.; Roy, V.; Russell, S. J.; Short, K. E.; Stewart, A. K.; Witzig, T. E.; Zeldenrust, S. R.; Dalton, R. J.; Rajkumar, S. V.; Bergsagel, P. L. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo. Clin. Proc. 2009, 84 (12), 1095-1110.
67. San Miguel, J.; Harousseau, J. L.; Joshua, D.; Anderson, K. C. Individualizing treatment of patients with myeloma in the era of novel agents. J. Clin. Oncol. 2008, 26 (16), 2761-2766.
68. Ludwig, H.; Beksac, M.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Cavo, M.; Dimopoulos, M.; Drach, J.; Einsele, H.; Facon, T.; Goldschmidt, H.; Harousseau, J. L.; Hess, U.; Ketterer, N.; Kropff, M.; Mendeleeva, L.; Morgan, G.; Palumbo, A.; Plesner, T.; San Miguel, J.; Shpilberg, O.; Sondergeld, P.; Sonneveld, P.; Zweegman, S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15 (1), 6-25.
69. Avet-Loiseau, H.; Soulier, J.; Fermand, J. P.; Yakoub-Agha, I.; Attal, M.; Hulin, C.; Garderet, L.; Belhadj, K.; Dorvaux, V.; Minvielle, S.; Moreau, P. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010, 24 (3), 623-628.
70. Richardson, P. G.; Weller, E.; Lonial, S.; Jakubowiak, A. J.; Jagannath, S.; Raje, N. S.; Avigan, D. E.; Xie, W.; Ghobrial, I. M.; Schlossman, R. L.; Mazumder, A.; Munshi, N. C.; Vesole, D. H.; Joyce, R.; Kaufman, J. L.; Doss, D.; Warren, D. L.; Lunde, L. E.; Kaster, S.; Delaney, C.; Hideshima, T.; Mitsiades, C. S.; Knight, R.; Esseltine, D. L.; Anderson, K. C. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116 (5), 679-686.
71. Dickens, N. J.; Walker, B. A.; Leone, P. E.; Johnson, D. C.; Brito, J. L.; Zeisig, A.; Jenner, M. W.; Boyd, K. D.; Gonzalez, D.; Gregory, W. M.; Ross, F. M.; Davies, F. E.; Morgan, G. J. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin. Cancer Res. 2010, 16 (6), 1856-1864.
72. Nair, B.; van Rhee, F.; Shaughnessy, J. D. Jr.; Anaissie, E.; Szymonifka, J.; Hoering, A.; Alsayed, Y.; Waheed, S.; Crowley, J.; Barlogie, B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115 (21), 4168-4173.
73. Haessler, J.; Shaughnessy, J. D. Jr.; Zhan, F.; Crowley, J.; Epstein, J.; van Rhee, F.; Anaissie, E.; Pineda-Roman, M.; Zangari, M.; Hollmig, K.; Mohiuddin, A.; Alsayed, Y.; Hoering, A.; Tricot, G.; Barlogie, B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin. Cancer Res. 2007, 13(23), 7073-7079.
74. Rajkumar, S. V. Treatment of myeloma: cure vs control. Mayo. Clin. Proc. 2008, 83 (10), 1142-1145.
75. Morabito, F.; Gentile, M.; Mazzone, C.; Bringhen, S.; Vigna, E.; Lucia, E.; Recchia, A. G.; Raimondo, F. D.; Musto, P.; Palumbo, A. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. Eur. J. Haematol. 2010, 85 (3), 181-191.
76. Rajkumar, S. V.; Rosinol, L.; Hussein, M.; Catalano, J.; Jedrzejczak, W.; Lucy, L.; Olesnyckyj, M.; Yu, Z.; Knight, R.; Zeldis, J. B.; Blade, J. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 2008, 26 (13), 2171-2177.
77. Rajkumar, S. V.; Jacobus, S.; Callander, N. S.; Fonseca, R.; Vesole, D. H.; Williams, M. E.; Abonour, R.; Siegel, D. S.; Katz, M.; Greipp, P. R. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010, 11 (1), 29-37.
78. Harousseau, J. L.; Attal, M.; Avet-Loiseau, H.; Marit, G.; Caillot, D.; Mohty, M.; Lenain, P.; Hulin, C.; Facon, T.; Casassus, P.; Michallet, M.; Maisonneuve, H.; Benboubker, L.; Maloisel, F.; Petillon, M. O.; Webb, I.; Mathiot, C.; Moreau, P. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J. Clin. Oncol. 2010, 28 (30), 4621-4629.
79. Reeder, C. B.; Reece, D. E.; Kukreti, V.; Chen, C.; Trudel, S.; Hentz, J.; Noble, B.; Pirooz, N. A.; Spong, J. E.; Piza, J. G.; Zepeda, V. H.; Mikhael, J. R.; Leis, J. F.; Bergsagel, P. L.; Fonseca, R.; Stewart, A. K. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009, 23 (7), 1337-1341.
80. Cavo, M.; Tacchetti, P.; Patriarca, F.; Petrucci, M. T.; Pantani, L.; Galli, M.; Di Raimondo, F.; Crippa, C.; Zamagni, E.; Palumbo, A.; Offidani, M.; Corradini, P.; Narni, F.; Spadano, A.; Pescosta, N.; Deliliers, G. L.; Ledda, A.; Cellini, C.; Caravita, T.; Tosi, P.; Baccarani, M. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376 (9758), 2075-2085.
81. Moreau, P.; Avet-Loiseau, H.; Facon, T.; Attal, M.; Tiab, M.; Hulin, C.; Doyen, C.; Garderet, L.; Randriamalala, E.; Araujo, C.; Lepeu, G.; Marit, G.; Caillot, D.; Escoffre, M.; Lioure, B.; Benboubker, L.; Pegourie, B.; Kolb, B.; Stoppa, A. M.; Fuzibet, J. G.; Decaux, O.; Dib, M.; Berthou, C.; Chaleteix, C.; Sebban, C.; Traulle, C.; Fontan, J.; Wetterwald, M.; Lenain, P.; Mathiot, C.; Harousseau, J. L. Bortezomib plus dexamethasone versus reduceddose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011, 118 (22), 5752-5758.
82. Kumar, S.; Flinn, I.; Richardson, P. G.; Hari, P.; Callander, N.; Noga, S. J.; Stewart, A. K.; Rifkin, R.; Wolf, J.; Estevam, J.; Mulligan, G.; Shi, H.; Webb, I. J.; Rajkumar, S. V. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, doi: 10.1182/blood-2011-11-395749.
83. Barlogie, B.; Anaissie, E.; van Rhee, F.; Haessler, J.; Hollmig, K.; Pineda-Roman, M.; Cottler-Fox, M.; Mohiuddin, A.; Alsayed, Y.; Tricot, G.; Bolejack, V.; Zangari, M.; Epstein, J.; Petty, N.; Steward, D.; Jenkins, B.; Gurley, J.; Sullivan, E.; Crowley, J.; Shaughnessy, J. D. Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br. J. Haematol. 2007, 138 (2), 176-185.
84. van Rhee, F.; Szymonifka, J.; Anaissie, E.; Nair, B.; Waheed, S.; Alsayed, Y.; Petty, N.; Shaughnessy, J. D. Jr.; Hoering, A.; Crowley, J.; Barlogie, B. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010, 116 (8), 1220-1227.
85. Attal, M.; Harousseau, J. L.; Facon, T.; Guilhot, F.; Doyen, C.; Fuzibet, J. G.; Monconduit, M.; Hulin, C.; Caillot, D.; Bouabdallah, R.; Voillat, L.; Sotto, J. J.; Grosbois, B.; Bataille, R. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2003, 349 (26), 2495-2502.
86. Cavo, M.; Tosi, P.; Zamagni, E.; Cellini, C.; Tacchetti, P.; Patriarca, F.; Di Raimondo, F.; Volpe, E.; Ronconi, S.; Cangini, D.; Narni, F.; Carubelli, A.; Masini, L.; Catalano, L.; Fiacchini, M.; de Vivo, A.; Gozzetti, A.; Lazzaro, A.; Tura, S.; Baccarani, M. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J. Clin. Oncol. 2007, 25 (17), 2434-2441.
87. Fermand, J. P.; Katsahian, S.; Divine, M.; Leblond, V.; Dreyfus, F.; Macro, M.; Arnulf, B.; Royer, B.; Mariette, X.; Pertuiset, E.; Belanger, C.; Janvier, M.; Chevret, S.; Brouet, J. C.; Ravaud, P. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J. Clin. Oncol. 2005, 23 (36), 9227-9233.
88. ClinicalTrials.gov Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (IFM/DFCI2009). http://www.clinicaltrials.gov/ct2/show/NCT01208662 (Accessed December 12, 2011).
89. ClinicalTrials. gov Study to compare VMP with HDM followed by VRD consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (HO95). http://www.clinicaltrials.gov/ct2/show/NCT01208766 (Accessed December 12, 2011).
90. Palumbo, A.; Bringhen, S.; Caravita, T.; Merla, E.; Capparella, V.; Callea, V.; Cangialosi, C.; Grasso, M.; Rossini, F.; Galli, M.; Catalano, L.; Zamagni, E.; Petrucci, M. T.; De Stefano, V.; Ceccarelli, M.; Ambrosini, M. T.; Avonto, I.; Falco, P.; Ciccone, G.; Liberati, A. M.; Musto, P.; Boccadoro, M. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367 (9513), 825-831.
91. Facon, T.; Mary, J. Y.; Hulin, C.; Benboubker, L.; Attal, M.; Pegourie, B.; Renaud, M.; Harousseau, J. L.; Guillerm, G.; Chaleteix, C.; Dib, M.; Voillat, L.; Maisonneuve, H.; Troncy, J.; Dorvaux, V.; Monconduit, M.; Martin, C.; Casassus, P.; Jaubert, J.; Jardel, H.; Doyen, C.; Kolb, B.; Anglaret, B.; Grosbois, B.; Yakoub-Agha, I.; Mathiot, C.; Avet-Loiseau, H. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007, 370 (9594), 1209-1218.
92. Wijermans, P.; Schaafsma, M.; Termorshuizen, F.; Ammerlaan, R.; Wittebol, S.; Sinnige, H.; Zweegman, S.; van Marwijk Kooy, M.; van der Griend, R.; Lokhorst, H.; Sonneveld, P. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J. Clin. Oncol. 2010, 28 (19), 3160-3166.
93. Hulin, C.; Facon, T.; Rodon, P.; Pegourie, B.; Benboubker, L.; Doyen, C.; Dib, M.; Guillerm, G.; Salles, B.; Eschard, J. P.; Lenain, P.; Casassus, P.; Azais, I.; Decaux, O.; Garderet, L.; Mathiot, C.; Fontan, J.; Lafon, I.; Virion, J. M.; Moreau, P. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 2009, 27 (22), 3664-3670.
94. Waage, A.; Gimsing, P.; Fayers, P.; Abildgaard, N.; Ahlberg, L.; Bjorkstrand, B.; Carlson, K.; Dahl, I. M.; Forsberg, K.; Gulbrandsen, N.; Haukas, E.; Hjertner, O.; Hjorth, M.; Karlsson, T.; Knudsen, L. M.; Nielsen, J. L.; Linder, O.; Mellqvist, U. H.; Nesthus, I.; Rolke, J.; Strandberg, M.; Sorbo, J. H.; Wisloff, F.; Juliusson, G.; Turesson, I. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010, 116 (9), 1405-1412.
95. Fayers, P. M.; Palumbo, A.; Hulin, C.; Waage, A.; Wijermans, P.; Beksaç, M.; Bringhen, S.; Mary, J. Y.; Gimsing, P.; Termorshuizen, F.; Haznedar, R.; Caravita, T.; Moreau, P.; Turesson, I.; Musto, P.; Benboubker, L.; Schaafsma, M.; Sonneveld, P.; Facon, T. Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network.Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011, 118 (5), 1239-1247.
96. Mateos, M. V.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; San Miguel, J. F. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 2010, 28 (13), 2259-2266.
97. Zonder, J. A.; Crowley, J.; Hussein, M. A.; Bolejack, V.; Moore, D. F., Sr.; Whittenberger, B. F.; Abidi, M. H.; Durie, B. G.; Barlogie, B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010, 116 (26), 5838-5841.
98. Palumbo, A.; Gay, F.; Falco, P.; Crippa, C.; Montefusco, V.; Patriarca, F.; Rossini, F.; Caltagirone, S.; Benevolo, G.; Pescosta, N.; Guglielmelli, T.; Bringhen, S.; Offidani, M.; Giuliani, N.; Petrucci, M. T.; Musto, P.; Liberati, A. M.; Rossi, G.; Corradini, P.; Boccadoro, M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidationmaintenance in untreated multiple myeloma patients. J. Clin. Oncol. 2010, 28 (5), 800-807. [Erratum, J. Clin. Oncol. 2010, 28 (13), 2314].
99. Mateos, M. V.; Oriol, A.; Martinez-Lopez, J.; Gutierrez, N.; Teruel, A. I.; de Paz, R.; Garcia-Larana, J.; Bengoechea, E.; Martin, A.; Mediavilla, J. D.; Palomera, L.; de Arriba, F.; Gonzalez, Y.; Hernandez, J. M.; Sureda, A.; Bello, J. L.; Bargay, J.; Penalver, F. J.; Ribera, J. M.; Martin-Mateos, M. L.; Garcia-Sanz, R.; Cibeira, M. T.; Ramos, M. L.; Vidriales, M. B.; Paiva, B.; Montalban, M. A.; Lahuerta, J. J.; Blade, J.; Miguel, J. F. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with ntreated multiple myeloma: a randomised trial. Lancet. Oncol. 2010, 11 (10), 934-941.
100. Lokhorst, H. M.; van der Holt, B.; Zweegman, S.; Vellenga, E.; Croockewit, S.; van Oers, M. H.; von dem Borne, P.; Wijermans, P.; Schaafsma, R.; de Weerdt, O.; Wittebol, S.; Delforge, M.; Berenschot, H.; Bos, G. M.; Jie, K. S.; Sinnige, H.; van Marwijk-Kooy, M.; Joosten, P.; Minnema, M. C.; van Ammerlaan, R.; Sonneveld, P. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and highdose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115 (6), 1113-1120.
101. Cavo, M.; Pantani, L.; Petrucci, M.T.; Patriarca, F.; Zamagni, E.; Donnarumma, D.; Crippa, C.; Boccadoro, M.; Perrone, G.; Falcone, A.; Nozzoli, C.; Zambello, R.; Masini, L.; Furlan, A.; Brioli, A.; Derudas, D.; Ballanti, S.; Dessanti, M.L.; De Stefano, V.; Carella, A.M.; Marcatti, M.; Nozza, A.; Ferrara, F.; Callea, V.; Califano, C.; Pezzi, A.; Baraldi, A.; Grasso, M.; Musto, P.; Palumbo, A. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 2012, doi: 10.1182/blood-2012-02-408898.
102. Barlogie, B.; Attal, M.; Crowley, J.; van Rhee, F.; Szymonifka, J.; Moreau, P.; Durie, B. G.; Harousseau, J. L. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J. Clin. Oncol. 2010, 28 (7), 1209-1214.
103. Offidani, M.; Corvatta, L.; Polloni, C.; Piersantelli, M. N.; Gentili, S.; Galieni, P.; Visani, G.; Alesiani, F.; Catarini, M.; Brunori, M.; Samori, A.; Burattini, M.; Centurioni, R.; Ferranti, M.; Giuliodori, L.; Candela, M.; Mele, A.; Marconi, M.; Leoni, P. Thalidomidedexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br. J. Haematol. 2009, 144 (5), 653-659.
104. Terpos, E.; Sezer, O.; Croucher, P. I.; Garcia-Sanz, R.; Boccadoro, M.; San Miguel, J.; Ashcroft, J.; Blade, J.; Cavo, M.; Delforge, M.; Dimopoulos, M. A.; Facon, T.; Macro, M.; Waage, A.; Sonneveld, P., The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol. 2009, 20 (8), 1303-1317.
105. Morgan, G.J.; Davies, F.E.; Gregory, W.M.; Szubert, A.J.; Bell, S.E.; Drayson, M.T.; Owen, R.G.; Ashcroft, A.J.; Jackson, G.H.; Child, J.A. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood 2012, doi:10.1182/blood-2011-11-392522.
106. Dickinson, M.; Prince, H. M.; Kirsa, S.; Zannettino, A.; Gibbs, S. D.; Mileshkin, L.; O'Grady, J.; Seymour, J. F.; Szer, J.; Horvath, N.; Joshua, D. E. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern. Med. J. 2009, 39 (5), 304-316.
107. Terpos, E.; Szydlo, R.; Apperley, J. F.; Hatjiharissi, E.; Politou, M.; Meletis, J.; Viniou, N.; Yataganas, X.; Goldman, J. M.; Rahemtulla, A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102 (3), 1064-1069.
108. Gavriatopoulou, M.; Dimopoulos, M. A.; Christoulas, D.; Migkou, M.; Iakovaki, M.; Gkotzamanidou, M.; Terpos, E. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert. Opin. Ther. Targets. 2009, 13 (7), 839-848.
109. Rizzo, J. D.; Somerfield, M. R.; Hagerty, K. L.; Seidenfeld, J.; Bohlius, J.; Bennett, C. L.; Cella, D. F.; Djulbegovic, B.; Goode, M. J.; Jakubowski, A. A.; Rarick, M. U.; Regan, D. H.; Lichtin, A. E. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J. Clin. Oncol. 2008, 26 (1), 132-149.
110. Leigh, B. R.; Kurtts, T. A.; Mack, C. F.; Matzner, M. B.; Shimm, D. S. Radiation therapy for the palliation of multiple myeloma. Int. J. Radiat. Oncol. Biol. Phys. 1993, 25 (5), 801-804.
111. Stewart, A. F. Clinical practice. Hypercalcemia associated with cancer. N. Engl. J. Med. 2005, 352 (4), 373-379.
112. Dimopoulos, M. A.; Kastritis, E.; Rosinol, L.; Blade, J.; Ludwig, H., Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22 (8), 1485-1493.
113. Nucci, M.; Anaissie, E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin. Infect. Dis. 2009, 49 (8), 1211-1225.
114. Palumbo, A.; Rajkumar, S. V.; Dimopoulos, M. A.; Richardson, P. G.; San Miguel, J.; Barlogie, B.; Harousseau, J.; Zonder, J. A.; Cavo, M.; Zangari, M.; Attal, M.; Belch, A.; Knop, S.; Joshua, D.; Sezer, O.; Ludwig, H.; Vesole, D.; Blade, J.; Kyle, R.; Westin, J.; Weber, D.; Bringhen, S.; Niesvizky, R.; Waage, A.; von Lilienfeld- Toal, M.; Lonial, S.; Morgan, G. J.; Orlowski, R. Z.; Shimizu, K.; Anderson, K. C.; Boccadoro, M.; Durie, B. G.; Sonneveld, P.; Hussein, M. A. Prevention of thalidomide- and lenalidomideassociated thrombosis in myeloma. Leukemia 2008, 22 (2), 414-423.
115. Delforge, M.; Blade, J.; Dimopoulos, M. A.; Facon, T.; Kropff, M.; Ludwig, H.; Palumbo, A.; Van Damme, P.; San-Miguel, J. F.; Sonneveld, P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet. Oncol. 2010, 11 (11), 1086-1095.
116. Zhou, Y.; Barlogie, B.; Shaughnessy, J. D. Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009, 23 (11), 1941-1956.
117. Ocio, E. M.; Mateos, M. V.; Maiso, P.; Pandiella, A.; San-Miguel, J. F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol. 2008, 9 (12), 1157-1165.